{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T08:36:00Z","timestamp":1772699760952,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Primary antibody deficiencies (PAD) are the most prevalent group of primary immunodeficiencies (PID) in adults and immunoglobulin replacement therapy (IRT) is the mainstay therapy to improve clinical outcomes. IRT is, however, expensive and, in minor PAD, clear recommendations concerning IRT are lacking. We conducted a retrospective real-life study to assess the effectiveness of low-dose IRT in minor PAD on 143 patients fulfilling European Society for Immunodeficiencies (ESID) diagnostic criteria for immunoglobulin (Ig)G subclass deficiency (IgGSD) or unclassified antibody deficiency (UAD). All patients were treated with intravenous low-dose IRT (0.14\u00a0\u00b1\u00a00.06 g\/kg\/month). Immunoglobulin (Ig) classes and IgG subclasses were measured at baseline and after 1\u00a0year of IRT. The annual rate of total infections, upper respiratory tract infections (URTI), lower respiratory tract infections (LRTI) and hospitalizations was measured at baseline and after 1 and 2 years of IRT. After 1 year of IRT significant improvement was demonstrated in: (a) serum IgG (787.9\u00a0\u00b1\u00a0229.3 versus 929.1\u00a0\u00b1\u00a0206.7\u00a0mg\/dl; p\u00a0&amp;lt;\u00a00.0001); (b) serum IgG subclasses (IgG1 = 351.4\u00a0\u00b1\u00a0109.9 versus 464.3\u00a0\u00b1\u00a0124.1, p\u00a0&amp;lt;\u00a00.0001; IgG2 = 259.1\u00a0\u00b1\u00a0140 versus 330.6\u00a0\u00b1\u00a0124.9, p\u00a0&amp;lt;\u00a00.0001; IgG3 = 50.2\u00a0\u00b1\u00a026.7 versus 55.6\u00a0\u00b1\u00a028.9\u00a0mg\/dl, p\u00a0&amp;lt;\u00a00.002); (c) annual rate of total infections (5.75\u00a0\u00b1\u00a03.87 versus 2.13\u00a0\u00b1\u00a01.74, p\u00a0&amp;lt;\u00a00.0001), URTI (1.48\u00a0\u00b1\u00a03.15 versus 0.69\u00a0\u00b1\u00a01.27; p\u00a0&amp;lt;\u00a00.005), LRTI (3.89\u00a0\u00b1\u00a03.52 versus 1.29\u00a0\u00b1\u00a01.37; p\u00a0&amp;lt;\u00a00.0001) and hospitalizations (0.37\u00a0\u00b1\u00a00.77 versus 0.15\u00a0\u00b1\u00a00.5; p\u00a0&amp;lt;\u00a00.0002). The improvement persisted after 2 years of IRT. No significant improvement in URTI annual rate was noted in UAD and in patients with bronchiectasis. In conclusion, low-dose IRT can improve clinical outcomes in UAD and IgGSD patients, providing a potential economical advantage over the standard IRT dose.<\/jats:p>","DOI":"10.1111\/cei.13629","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T17:12:04Z","timestamp":1622567524000},"page":"346-353","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness of low-dose intravenous immunoglobulin therapy in minor primary antibody deficiencies: A 2-year real-life experience"],"prefix":"10.1093","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5955-5076","authenticated-orcid":false,"given":"Emanuele","family":"Vivarelli","sequence":"first","affiliation":[{"name":"Immunoallergology Unit, Careggi University Hospital, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Matucci","sequence":"additional","affiliation":[{"name":"Immunoallergology Unit, Careggi University Hospital, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Bormioli","sequence":"additional","affiliation":[{"name":"Immunoallergology Unit, Careggi University Hospital, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Parronchi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Immunology and Cell Therapy Unit, Careggi University Hospital, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Liotta","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Immunology and Cell Therapy Unit, Careggi University Hospital, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Cosmi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Immunology and Cell Therapy Unit, Careggi University Hospital, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Almerigogna","sequence":"additional","affiliation":[{"name":"Immunoallergology Unit, Careggi University Hospital, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[{"name":"Immunoallergology Unit, Careggi University Hospital, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"2021121100020958500_cei13629-bib-0001","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-981-15-3532-1_10","article-title":"Primary antibody deficiencies","volume":"1254","author":"Min","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"2021121100020958500_cei13629-bib-0002","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3389\/fimmu.2020.00522","article-title":"Bronchiectasis in primary antibody deficiencies: a multidisciplinary approach","volume":"31","author":"Wall","year":"2020","journal-title":"Front Immunol"},{"key":"2021121100020958500_cei13629-bib-0003","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3389\/fimmu.2018.01837","article-title":"The lung in primary immunodeficiencies: new concepts in infection and inflammation","volume":"8","author":"Baumann","year":"2018","journal-title":"Front Immunol"},{"key":"2021121100020958500_cei13629-bib-0004","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13023-018-0941-0","article-title":"The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data","volume":"13","author":"Odnoletkova","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"2021121100020958500_cei13629-bib-0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.rmed.2017.10.016","article-title":"Primary immune deficiency diseases as unrecognized causes of chronic respiratory disease","volume":"132","author":"Berger","year":"2017","journal-title":"Respir Med"},{"key":"2021121100020958500_cei13629-bib-0006","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaci.2013.02.028","article-title":"Controversies in IgG replacement therapy in patients with antibody deficiency diseases","volume":"131","author":"Gelfand","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2021121100020958500_cei13629-bib-0007","article-title":"Immunoglobulin replacement therapy versus antibiotic prophylaxis as treatment for incomplete primary antibody deficiency","author":"Smits","year":"2020","journal-title":"J Clin Immunol"},{"key":"2021121100020958500_cei13629-bib-0008","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jaci.2015.07.016","article-title":"Immunoglobulin deficiency in patients with chronic rhinosinusitis: systematic review of the literature and meta-analysis","volume":"136","author":"Schwitzgu\u00e9bel","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2021121100020958500_cei13629-bib-0009","doi-asserted-by":"crossref","first-page":"e0172437","DOI":"10.1371\/journal.pone.0172437","article-title":"Antibody deficiency in patients with frequent exacerbations of chronic obstructive pulmonary disease (COPD)","volume":"12","author":"McCullagh","year":"2017","journal-title":"PLOS ONE"},{"key":"2021121100020958500_cei13629-bib-0010","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"2021121100020958500_cei13629-bib-0011","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.tmrv.2009.09.011","article-title":"The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline","volume":"24","author":"Shehata","year":"2010","journal-title":"Transfus Med Rev"},{"key":"2021121100020958500_cei13629-bib-0012","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12026-011-8241-y","article-title":"Global study of primary immunodeficiency diseases (PI) \u2013 diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation","volume":"51","author":"Modell","year":"2011","journal-title":"Immunol Res"},{"key":"2021121100020958500_cei13629-bib-0013","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.iac.2008.07.003","article-title":"Management of primary antibody deficiency with replacement therapy: summary of guidelines","volume":"28","author":"Roifman","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"2021121100020958500_cei13629-bib-0014","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10875-011-9511-0","article-title":"IPINet Investigators. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study","volume":"31","author":"Quinti","year":"2011","journal-title":"J Clin Immunol"},{"key":"2021121100020958500_cei13629-bib-0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.iac.2018.08.001","article-title":"Personalized therapy: immunoglobulin replacement for antibody deficiency","volume":"39","author":"Wasserman","year":"2019","journal-title":"Immunol Allergy Clin North Am"},{"key":"2021121100020958500_cei13629-bib-0016","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/00365540600951192","article-title":"Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long-term follow-up","volume":"39","author":"Olinder-Nielsen","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"2021121100020958500_cei13629-bib-0017","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000199723","article-title":"Efficacy of intravenous gammaglobulin for immunoglobulin G subclass and\/or antibody deficiency in adults","volume":"149","author":"Abdou","year":"2009","journal-title":"Int Arch Allergy Immunol"},{"key":"2021121100020958500_cei13629-bib-0018","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2249.2009.04062.x","article-title":"Immunological and clinical profile of adult patients with selective immunoglobulin subclass deficiency: response to intravenous immunoglobulin therapy","volume":"159","author":"Abrahamian","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"2021121100020958500_cei13629-bib-0019","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00005-019-00556-3","article-title":"Clinical and immunological features of 78 adult patients with primary selective IgG subclass deficiencies","volume":"67","author":"Khokar","year":"2019","journal-title":"Arch Immunol Ther Exp"},{"key":"2021121100020958500_cei13629-bib-0020","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jaip.2019.02.004","article-title":"The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity","volume":"7","author":"Seidel","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2021121100020958500_cei13629-bib-0021","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"2021121100020958500_cei13629-bib-0022","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s10875-020-00773-y","article-title":"Immunological and clinical phenotyping in primary antibody deficiencies: a growing disease spectrum","volume":"40","author":"Shin","year":"2020","journal-title":"J Clin Immunol"},{"key":"2021121100020958500_cei13629-bib-0023","first-page":"122","article-title":"Evaluation of pulmonary complications in patients with primary immunodeficiency disorders","volume":"49","author":"Reisi","year":"2017","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"2021121100020958500_cei13629-bib-0024","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12026-017-8907-1","article-title":"Modeling strategy to identify patients with primary immunodeficiency utilizing risk management and outcome measurement","volume":"65","author":"Modell","year":"2017","journal-title":"Immunol Res"},{"key":"2021121100020958500_cei13629-bib-0025","first-page":"S105","article-title":"Managing cost of care and healthcare utilization in patients using immunoglobulin agents","volume":"25","author":"Vaughan","year":"2019","journal-title":"Am J Manag Care"},{"key":"2021121100020958500_cei13629-bib-0026","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1586\/1744666X.2015.1029457","article-title":"Economic burden of common variable immunodeficiency: annual cost of disease","volume":"11","author":"Sadeghi","year":"2015","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cei.13629","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cei.13629","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/205\/3\/346\/41591442\/cei13629.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/205\/3\/346\/41591442\/cei13629.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:25:30Z","timestamp":1641054330000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/205\/3\/346\/6431030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,6,28]]},"published-print":{"date-parts":[[2021,8,18]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13629","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9]]},"published":{"date-parts":[[2021,6,28]]}}}